LYN 072
Alternative Names: LYN-072; Ultra-long acting oral HIV therapeutic - LyndraLatest Information Update: 28 Feb 2022
At a glance
- Originator Lyndra
- Class Antiretrovirals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in HIV-infections in USA (PO, Controlled release)
- 10 Dec 2018 Lyndra Therapeutics receives a notice of allowance from USPTO for its ultra-long-acting oral drug delivery system in USA
- 27 Apr 2018 Lyndra enters into a Joint Venture with Global Drug Commercialization Center to commercialise its ultra-long acting oral therapeutics in China